We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | NASDAQ:BIIB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.27 | 2.00% | 217.78 | 217.78 | 346.20 | 217.88 | 213.11 | 215.30 | 1,144,156 | 05:00:09 |
From May 2019 to May 2024
By Colin Kellaher
Biogen Inc. (BIIB) on Tuesday said Michael Ehlers is stepping down as executive vice president of research and development to pursue a new opportunity.
The Cambridge, Mass., biopharmaceutical company said Chief Medical Officer Alfred Sandrock Jr. will assume the additional post of executive vice president of research and development, and said it named Alphonse Galdes executive vice president of pharmaceutical operations and technology.
Mr. Ehlers has been head of R&D at Biogen since joining from Pfizer Inc. (PFE) in 2016.
Mr. Sandrock, who joined Biogen in 1998, has been chief medical officer since 2012 and a member of the company's executive committee since 2015.
Mr. Galdes, who joining Biogen in 1995, had been serving as senior vice president of asset development and portfolio management.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 01, 2019 08:44 ET (12:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Biogen Chart |
1 Month Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
